Find a Cancer Program  Log in to MyNetwork
Facebook  LinkedIn  Twitter  ACCC Youtube Channel

Search Drug Alphabetically

Generic Name Belinostat
Brand Name Beleodaq®
Payment Category Medicare Part B
Year Introduced 2014
Type of Drug Histone deacetylase inhibitor
Manufacturer Acrotech Biopharma
Medical Affairs Questions (date verified) 888.292.9617
Coverage & Reimbursement Questions 888.537.8277
HCPCS J9032
Billing Unit 10 mg
Medicare Payment Limit (Effective January 1, 2021) $42.70

FDA-Approved Indication(s)

  • indicated for the treatment of patients with relapsed or refractory peripheral T-cell lymphoma. (7/3/14)

Approved Indication(s) with Orphan Drug Status Treatment of peripheral T-cell lymphoma
ICD-10 Code(s) for Labeled Indication(s) Peripheral T-cell lymphoma [C84.4x]
Name Strength Form Package Labeler NDC

Copyright © 2021 Association of Community Cancer Centers. All Rights Reserved.
11600 Nebel Street, Suite 201, Rockville, MD 20852  |  Tel.: 301.984.9496  |  Fax: 301.770.1949

CONTACT US